<DOC>
	<DOCNO>NCT01224171</DOCNO>
	<brief_summary>This study patient moderately severely active Crohn 's disease design establish efficacy safety vedolizumab induction clinical response remission .</brief_summary>
	<brief_title>Study Vedolizumab Patients With Moderate Severe Crohn 's Disease</brief_title>
	<detailed_description>After complete study , patient eligible enroll long term safety study continue access vedolizumab ( study C13008 ; NCT00790933 ) study drug well tolerate , major surgical intervention Crohn 's disease occur require . Participants enroll Study C13008 complete Final Safety visit ( 16 week last dose study drug ) maximum time study 22 week .</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Vedolizumab</mesh_term>
	<criteria>Age 18 80 Diagnosis moderately severely active Crohn 's disease Crohn 's Disease involvement ileum and/or colon Demonstrated , previous 5 year period , inadequate response , loss response , intolerance least one conventional therapy define protocol May receive therapeutic dose conventional therapy inflammatory bowel disease ( IBD ) define protocol Exclusion Criteria Evidence abdominal abscess initial screen visit Extensive colonic resection , subtotal total colectomy History &gt; 3 small bowel resection diagnosis short bowel syndrome Ileostomy , colostomy , know fix symptomatic stenosis intestine Have receive non permitted therapy within either 30 60 day , depend medication , state protocol Chronic hepatitis B C infection ; human immunodeficiency virus ( HIV ) infection Active latent tuberculosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>